Proton Therapy as a Bridging Treatment in CAR T-Cell Therapy for Relapsed and Refractory Large B-Cell Lymphoma: Is There a Role?

Diffuse large B-cell lymphoma (DLBCL) is the most common type of non-Hodgkin lymphoma. Since the relapse rate of DLBCL to frontline chemoimmunotherapy and salvage autologous hematopoietic cell transplant is high, CD19-directed chimeric antigen receptor (CAR) T-cell therapy was adopted. Given the tim...

詳細記述

書誌詳細

出版年:	International Journal of Particle Therapy
主要な著者:	Omran Saifi, MD, Mohamed A. Kharfan-Dabaja, MD, MBA, Youssef H. Zeidan, MD, PhD, Jennifer Peterson, MD, William G. Rule, MD, Scott C. Lester, MD, Bradford S. Hoppe, MD, MPH
フォーマット:	論文
言語:	英語
出版事項:	Elsevier 2020-06-01
主題:	car t-cell therapy proton therapy bridging therapy non-hodgkin lymphoma
オンライン･アクセス:	https://theijpt.org/doi/pdf/10.14338/IJPT-20-00004.1